Research Project · Health
Biomarker development for combined PD1+LAG3 inhibition in RRD glioblastoma
Cannonball Kids' Cancer; co-funded by Kindred Foundationcannonballkidscancer.org (opens in a new tab)Catalog updated
- Amount
- $100,000
- Program type
- Research Project
- Field
- Health
- Eligible career stages
- Not listed
About this program
The Cannonball Kids' Cancer Foundation, in partnership with the Kindred Foundation, offers a $100,000 grant to support biomarker development for combined PD1+LAG3 inhibition in recurrent/refractory (RRD) glioblastoma. This funding aims to validate immune response biomarkers in patients treated with a novel therapy, potentially leading to a larger clinical trial and improved standard of care for this aggressive disease. Eligibility criteria are not specified, but the focus is on researchers working in pediatric and young adult glioblastoma with expertise in immunotherapy and biomarker development.
In FundFit
Full eligibility
Source announcement
Similar programs
These details are in FundFit.